April 12, 2018 : Latest SGLT-2 Inhibitors News

• Study Explores Mechanisms Behind Cardiovascular Benefits of SGLT2 inhibitors
• Lower Death Risk with SGLT2 Inhibitors in Patients with Type 2 Diabetes
• Behind Empagliflozin’s Reduction in Cardiovascular Mortality
• Benefit of Canagliflozin In Patients with Type 2 Diabetes

• Exclusive Interview: Yehuda Handelsman, Prescribing SGLT 2 Inhibitors

As I was reviewing this months SGLT-2 Therapy edition I was reminded of how much this class of drugs has opened up dialogues on patient care in multiple disease states. With the older diabetes medications we talked A1c, Fasting, or Postprandial; all related to diabetes and there was not much else. Now with the wider acceptance and increased research on the SGLT-2’s we find ourselves talking about Cardiovascular Benefits, Weight Loss, Decreased Mortality as well as improved glucose levels.

This month one of the most knowledgeable thought leaders in the diabetes world, Yehuda Handelsman, shares his ideas for prescribing SGLT-2 Inhibitors.

Dave Joffe

Editor-in-chief

Researchers complete examination of class of type 2 medication.

It is unclear whether SGLT2i show reduction in mortality in all patients with type 2 or just in patients with type 2 diabetes with increased cardiovascular risk.

Post-hoc analysis of the breakthrough EMPA-REG Outcome trial demonstrated reduction in composite cardiovascular outcomes that can be seen with empagliflozin therapy.

Canagliflozin is found to have reduced risk of cardiovascular death or hospitalization due to heart failure in type 2 diabetes patients.

In part 2 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the actual cost to the lives of patients who are put on more expensive, but life-saving, diabetes drugs.